U.S. Industrial REITs Stock News

CytomX Therapeutics earnings and Varseta-M data come into focus CytomX Therapeutics (CTMX) is back on radar after reporting full year 2025 results alongside early Phase 1 expansion data for its EpCAM-targeting ADC, Varseta-M, in late-line metastatic colorectal cancer. See our latest analysis for CytomX Therapeutics. The recent Varseta-M data, full year 2025 results and a new shelf registration plus follow-on equity filing have coincided with sharp share price momentum, with a 1 day share...

Iron Mountain (NYSE:IRM) has agreed to acquire ACT Logistics in Australia as part of its global expansion. The company continues to grow its data center segment, adding to its traditional records management operations. Iron Mountain recently raised its dividend by 10%, highlighting its focus on shareholder returns. Iron Mountain, best known for records storage and information management, is in the middle of a meaningful shift in where its business is growing. The ACT Logistics deal broadens...

Invesco, NYSE:IVZ, has introduced an employee benefit that supports new U.S. government "Trump Accounts" under Section 530A child savings accounts. The company plans to match the initial government contribution for eligible children of its employees, adding a private employer layer to the federal program. This move links Invesco's employee benefits directly to a current policy initiative focused on long term child savings. For investors tracking NYSE:IVZ, this new benefit sits alongside a...

The Morning Bull - US Market Morning Update Tuesday, Mar, 17 2026 E-mini S&P 500 futures are pointing higher this morning, up about 0.4%, as investors juggle mixed US factory data and rising pressure from the bond market. The NY Empire State Manufacturing Index sits at -0.2 in March, which means activity in New York factories has essentially stalled, a concern for jobs and overtime pay in industrial regions. At the same time, the 10 year US Treasury yield is holding near 4.24%, keeping...

Stock performance context for CorMedix Without a specific news catalyst driving fresh headlines, CorMedix (CRMD) continues to draw attention as investors weigh its recent share performance in relation to its role in developing therapies for life threatening conditions. The stock last closed at US$6.54, with returns showing mixed momentum. It recorded a 1.4% gain over the past day, alongside a slight decline over the past week. See our latest analysis for CorMedix. Recent trading tells a mixed...

Silvaco Group (SVCO) surprised the market with quarterly results that came in ahead of expectations, along with revenue guidance above earlier forecasts and cost cuts tracking better than management initially outlined. See our latest analysis for Silvaco Group. Silvaco Group’s recent earnings beat and upbeat guidance have been met with sharp share price momentum, with a 7 day share price return of 53.5% and a year to date share price return of 22%, even though the 1 year total shareholder...

Townsquare Media (TSQ) FY 2025 Earnings Snapshot Townsquare Media (TSQ) has wrapped up FY 2025 with Q4 revenue of US$106.5 million and a basic EPS loss of US$0.32, while trailing twelve month figures show revenue at US$427.4 million and a basic EPS loss of US$0.71. Over recent quarters the company has seen revenue move from US$117.8 million in Q4 2024 to US$106.5 million in Q4 2025, with EPS shifting from a profit of US$1.59 to a loss of US$0.32. This sets up a story where revenue is...

Cytokinetics (NasdaqGS:CYTK) presented new clinical data on MYQORZO (aficamten) for obstructive hypertrophic cardiomyopathy at a major cardiology conference. The updates covered exercise capacity outcomes, effectiveness across patients with and without hypertension, and safety during treatment interruption and restart. The new analyses expand the clinical profile of MYQORZO, a recently approved oHCM therapy, and add detail on how the drug performs in real treatment scenarios. Cytokinetics...

Wondering whether ServisFirst Bancshares is attractively priced at its current level? This article focuses squarely on what the recent share performance might be telling you about value. The stock last closed at US$73.73, with returns of 2.7% year to date, a 14.4% decline over the past month, and a 9.7% decline over the past year, while still showing a 35.2% gain over three years and 31.1% over five years. These mixed returns have kept ServisFirst Bancshares on the radar for investors who...

Telos (TLS) just closed out FY 2025 with Q4 revenue of US$46.8 million and a basic EPS loss of US$0.22, capping a year in which trailing twelve month revenue came in at US$164.8 million and EPS on the same basis was a loss of US$0.50. Over recent quarters the company has seen revenue move from US$26.4 million in Q4 2024 to US$30.6 million in Q1 2025, US$36.0 million in Q2, US$51.4 million in Q3, and US$46.8 million in Q4, while quarterly basic EPS losses ranged between US$0.03 and US$0.22...

Lifecore Biomedical (LFCR) just posted its FY 2025 fourth quarter numbers, with revenue of US$36.4 million and a basic EPS loss of US$0.06. This sets the tone for a year where the trailing twelve months show revenue at about US$129.5 million and a basic EPS loss of US$0.92. Over recent quarters, revenue has moved from US$24.7 million in Q1 FY 2025 to US$31.1 million in Q3 and then US$36.4 million in Q4. Quarterly basic EPS losses ranged from US$0.53 in Q1 to US$0.29 in Q3 and US$0.06 in Q4,...

Zepp Health (ZEPP) has wrapped up FY 2025 with fourth quarter revenue of US$85.2 million and a basic EPS loss of US$0.69, setting the tone for how you might read the full year at the current share price of US$16.22. The company has seen quarterly revenue move from US$59.5 million in Q4 2024 to US$85.2 million in Q4 2025, while basic EPS over that stretch has shifted from a loss of US$2.29 to a loss of US$0.69. This puts the focus squarely on how sustainably margins can tighten those losses...

Latest FY 2025 Earnings Snapshot WaterBridge Infrastructure (WBI) just posted its FY 2025 numbers with third quarter revenue of US$123.25 million and a basic EPS loss of US$0.02, while net income excluding extra items was a loss of US$0.67 million. The company has seen revenue move from US$89.80 million in the third quarter of 2024 to US$123.25 million in the same period of 2025. The trailing twelve month revenue figure in the dataset stands at US$733.30 million with a net loss of US$91.25...

Apellis Pharmaceuticals recently added Mikael Dolsten, M.D., Ph.D., former chief scientific officer of Pfizer, to its board of directors, bringing decades of high-level research and development leadership across major global drug makers. This appointment, alongside growing analyst interest in Apellis’s key products Empaveli and Syfovre, underscores how external experts view the company’s pipeline and commercial portfolio as increasingly relevant in rare kidney disease and eye care...

First Bancorp (NasdaqGS:FBNC) announced the retirement of Michael G. Mayer from his roles as President and CEO of First Bank. Mayer is stepping back from day to day management but will continue to serve on the company’s Board of Directors. The change marks a leadership transition at the top of First Bank’s operating structure. First Bancorp, the holding company for First Bank, operates as a regional banking platform, offering lending, deposit, and related financial services. Leadership...

Certara (CERT) is back on investors’ radar after closing 2025 with revenue of US$418.8m, a small net loss, and fresh FDA validation of its biosimulation platform through PBPK modeling used in the asciminib NDA. See our latest analysis for Certara. Despite FDA validation for its PBPK work and new software launches, Certara’s share price has been under pressure, with a 90 day share price return of 23.91% and a 1 year total shareholder return of 39.10%. This may indicate fading momentum after...

If you are wondering whether Sirius XM Holdings is still worth a place in your portfolio at today’s price, this article walks through what the current market valuation might be implying. The stock recently closed at US$21.99, with returns of 3.3% over the past 30 days, 7.2% year to date, 2.0% over the last year, and longer term 3 year and 5 year returns of 32.5% and 56.9% declines respectively. This tells a very different story depending on your time frame. Recent coverage has focused on...

Terns Pharmaceuticals recently attracted renewed attention after updating its corporate presentation with refreshed pipeline timelines and milestones, while also being selected for inclusion in a STOXX benchmark index effective March 23, 2026. This combination of clearer development visibility, impending index inclusion, and investor focus on the upcoming earnings update has sharpened debate around the company’s long-term prospects and current financial pressures. With investors now closely...

In March 2026, Codexis reported fourth-quarter 2025 results showing revenue of US$38.92 million and net income of US$9.6 million, reversing a prior-year loss and beating analyst expectations, alongside full-year 2025 revenue of US$70.39 million and guidance for 2026 revenue of US$72 million to US$76 million. The quarter was heavily influenced by a large technology transfer agreement with Merck and growing ECO Synthesis platform activity, which also underpins management’s view that existing...

This article examines whether Petco Health and Wellness Company, at around US$3.62, may represent a bargain or a value trap by exploring what the current share price might indicate about the business. The stock has recently experienced sharp moves, with returns of 52.1% over the last 7 days, 44.2% over the last 30 days, 27.0% year to date and 51.5% over the last year. However, the 3 year and 5 year returns show declines of 63.1% and 84.4%, which tells a very different story. These swings...

In March 2026, Silvaco Group, Inc. completed a follow-on at-the-market US$15 million common stock offering and reported full-year 2025 revenue of US$63.06 million with a net loss of US$41.21 million, alongside guidance for first-quarter 2026 revenue of US$15 million to US$19 million. A few days earlier, the company also announced the immediate availability of Mixel MIPI Production Ready Offerings, broadening its silicon-proven mixed-signal interface IP portfolio across advanced process nodes...

Earlier this week, Kyivstar Group Ltd. reported its full-year 2025 results, with sales rising to US$1,157 million from US$919 million, even as net income fell to US$124 million from US$283 million and basic EPS from continuing operations declined to US$0.57 from US$1.37. The company also issued 2026 guidance calling for USD revenue growth of 8%–11%, underlining management’s confidence in further expanding its fast-growing digital and connectivity ecosystem despite a volatile operating...

Civitas Resources previously reported full-year 2025 results showing revenue of US$4,393 million and net income of US$561 million, both lower than the prior year, while SM Energy, which assumed Civitas’s 8.375% Senior Notes due 2028 after their merger, launched a cash tender offer for up to US$750 million of those notes. This combination of softer earnings and an offer to repurchase a large portion of high-coupon debt highlights how the merged business is balancing profitability pressures...

Intrepid Potash, Inc. has reported improved fourth-quarter 2025 results with sales rising to US$75.88 million and net loss narrowing to US$0.429 million, while also confirming sales and production guidance for potash and Trio in 2026. At the same time, an updated Technical Report Summary for the White Silver Lithium Project underscores Intrepid’s move into battery-grade lithium production using by-product brine at its Wendover, Utah facility, highlighting a new domestic source of critical...